(Cedazuridine + decitabine) is a Small Molecule owned by Otsuka Pharmaceutical, and is involved in 33 clinical trials, of which 3 were completed, 27 are ongoing, and 3 are planned.
ASTX-727 acts as hypomethylating agent (HMA). Decitabine incorporates into DNA and inhibits DNA methyltransferase-1 which results in hypomethylation of DNA and intra-S-phase arrest of DNA replication. E-7727 acts as cytidine deaminase inhibitor. Cytidine deaminase (CDA) is an enzyme that is responsible for the degradation of nucleosides, including decitabine. E-7727 by inhibiting CDA, inhibits degradation of decitabine. Decitabine induced hypomethylation in neoplastic cells restores normal function to genes that are critical for the control of cellular differentiation and proliferation.
The revenue for (Cedazuridine + decitabine) is expected to reach a total of $1.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Cedazuridine + decitabine) NPV Report.
(Cedazuridine + decitabine) was originated by Teva Pharmachemie and Eisai and is currently owned by Otsuka Pharmaceutical. Otsuka Holdings is the other company associated in development or marketing of (Cedazuridine + decitabine).
(Cedazuridine + decitabine) Overview
Cedazuridine and Decitabine (Inqovi) is a fixed dose combination act as an anti-neoplastic agent. it is formulates ad film coated tablets for oral route of administration. Inqovi is indicated for the treatment of adult patients with myelodysplastic syndrome with french american british subtypes refractory anemia with ringed sideroblast, refractory anemia with excess blasts and chronic myelomonocytic leukemia.
ASTX-727 (fixed dose combination of decitabine and cedazuridine (E-7727)) is under development for the treatment of metastatic mucosal melanoma, metastatic castrate resistant prostate cancer (mCRPC), newly diagnosed acute myeloid leukemia (AML), newly diagnosed chronic myeloid leukemia, relapsed and refractory acute myeloid leukemia, peripheral nerve sheath tumor (neurofibrosarcoma), low grade gliomas, triple negative breast cancer and hormone resistant/HER2-negative metastatic breast cancer, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), myeloproliferative neoplasms, relapsed and refractory overlap syndromes and solid tumors. The drug candidate formulated as tablet and is administered orally in the form of tablet. Decitabine is a cytidine antimetabolite analogue that inhibits DNA methyltransferase-1. E-7727 is a new molecular entity (NME) that inhibits cytidine deaminase (CDA) activity. It is developed based on Pyramid technology.
Otsuka Holdings Overview
Otsuka Holdings (Otsuka) is a holding company, which operates various businesses such as pharmaceuticals, nutraceuticals, consumer products and other businesses through its subsidiaries. It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies. The company’s product portfolio includes pharmaceutical products, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals, medical devices and OTC products. It markets its products in North America, Europe, and Asia. Otsuka is headquartered in Chiyoda-ku, Tokyo, Japan.
The company reported revenues of (Yen) JPY1,498,276 million for the fiscal year ended December 2021 (FY2021), an increase of 5.3% over FY2020. In FY2021, the company’s operating margin was 10.3%, compared to an operating margin of 13.8% in FY2020. In FY2021, the company recorded a net margin of 8.4%, compared to a net margin of 10.4% in FY2020.
The company reported revenues of JPY451,811 million for the third quarter ended September 2022, an increase of 4.1% over the previous quarter.
Quick View – (Cedazuridine + decitabine)
| Report Segments |
|
| Drug Name |
|
| Administration Pathway |
|
| Therapeutic Areas |
|
| Key Companies |
|
| Highest Development Stage |
|
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
